Plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children

Rachida Tahar, Catarina Albergaria, Neil Zeghidour, Vincent Foumane Ngane, Léonardo K. Basco, Christian RoussilhonMalaria 2016 · DOI

Abstract: The results indicate that the simultaneous evaluation of these bioactive molecules as quantifiable blood parameters may be helpful to get a better insight into the clinical syndromes in children with malaria.

Introduction

Malaria is not a binary state; it is a complex clinical spectrum. In endemic regions, children may present with asymptomatic malaria (AM), uncomplicated malaria (UM), or progress to life-threatening severe malaria (SM) or cerebral malaria (CM). The biological "switch" that triggers this progression remains poorly understood, and clinicians lack reliable, quantifiable biomarkers to predict which children are at risk of clinical deterioration. This study, published in the Malaria Journal, investigates the "immunological fingerprint" of children across this spectrum to identify multi-marker panels that define specific clinical states.

Methods

Researchers conducted a cross-sectional study in Cameroon involving 215 children (aged 4 months to 12 years). Participants were categorized into four groups: AM (n=80), UM (n=69), SM (n=41), and CM (n=25). A recovery group of 39 UM children was also re-tested 28 days post-treatment (UM-D28). Plasma concentrations of eight mediators were measured via ELISA:

  • Neopterin (immune activation)
  • sCD163 & sCD14 (monocyte/macrophage activation)
  • suPAR (inflammation/tissue damage)
  • Pentraxin 3 (PTX3) (innate immunity)
  • Fractalkine (CX3CL1) (chemokine/adhesion)
  • sTREM-1 (inflammatory amplifier)
  • MIG (CXCL9) (T-cell chemoattractant)

Statistical tools including ROC curve analysis and Principal Component Analysis (PCA) were used to determine diagnostic accuracy and identify biomarker clusters.

Results and Key Insights

The Immunological Fingerprint

The study revealed that specific combinations of biomarkers, rather than any single molecule, accurately map the clinical spectrum of Plasmodium falciparum malaria. As shown in the comparative ratios below, each clinical state possesses a unique profile relative to healthy controls.

Figure 5: Biomarker:CTS ratios across different clinical malaria conditions, illustrating the unique 'fingerprint' of each state.

Clinical Progression and Severity Markers

  • The "Tolerance" Profile: Children with AM exhibited high levels of Fractalkine and sCD163, suggesting these molecules may help maintain a protective, low-grade inflammatory state.
  • PTX3 as a "Mild" Marker: Pentraxin 3 (PTX3) was the primary responder in uncomplicated malaria (UM), showing a significant spike compared to AM. It was also the only marker to correlate significantly with parasitemia (R = 0.444).
  • The Severe Transition: As the disease progresses to SM or CM, the profile shifts dramatically. Neopterin and suPAR levels skyrocket, while Fractalkine levels crash, signaling a loss of homeostatic control.
Figure 6: Fold changes of the eight mediators across the clinical spectrum, highlighting the rise of Neopterin and the crash of Fractalkine in severe cases.

Diagnostic Accuracy

Neopterin emerged as a near-perfect discriminator for severe disease (SM-CM) versus uncomplicated malaria (UM), achieving an Area Under the Curve (AUC) of 1.000. For distinguishing asymptomatic cases from healthy controls, Fractalkine and sCD163 were highly effective (AUCs of 0.985 and 0.959, respectively). PCA identified the combination of Neopterin, suPAR, and Fractalkine as the strongest predictor for severe outcomes.

Discussion and Limitations

While the study provides a robust descriptive map of malaria pathogenesis, several limitations exist. The AM group was significantly older than the symptomatic groups, which may introduce age-related immunity as a confounding factor. Additionally, the healthy control group consisted of French Caucasians, which may not fully reflect the genetic or environmental background of the Cameroonian population.

Future longitudinal studies are required to determine if these biomarker profiles can predict progression before clinical deterioration occurs, potentially transforming these insights into life-saving diagnostic tools.

Summary updated

Abstract

The results indicate that the simultaneous evaluation of these bioactive molecules as quantifiable blood parameters may be helpful to get a better insight into the clinical syndromes in children with malaria.
BibTeX
@inproceedings{tahar2016plasma,
  author = {Rachida Tahar and Catarina Albergaria and Neil Zeghidour and Vincent Foumane Ngane and Léonardo K. Basco and Christian Roussilhon},
  title = {{Plasma levels of eight different mediators and their potential as biomarkers of various clinical malaria conditions in African children}},
  booktitle = {Malaria},
  year = {2016},
  doi = {10.1186/s12936-016-1378-3},
}
Figure